MA28946B1 - Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinase - Google Patents
Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinaseInfo
- Publication number
- MA28946B1 MA28946B1 MA29848A MA29848A MA28946B1 MA 28946 B1 MA28946 B1 MA 28946B1 MA 29848 A MA29848 A MA 29848A MA 29848 A MA29848 A MA 29848A MA 28946 B1 MA28946 B1 MA 28946B1
- Authority
- MA
- Morocco
- Prior art keywords
- methylpiperazin
- ylamino
- benzamide
- pyrimidin
- ylmethyl
- Prior art date
Links
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title abstract 6
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 title 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 title 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 title 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 3
- 229960002411 imatinib Drugs 0.000 abstract 3
- 230000002025 microglial effect Effects 0.000 abstract 2
- 208000006332 Choriocarcinoma Diseases 0.000 abstract 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 abstract 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 abstract 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000003914 endometrial carcinoma Diseases 0.000 abstract 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 abstract 1
- 229940080856 gleevec Drugs 0.000 abstract 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 abstract 1
- 201000006812 malignant histiocytosis Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000306 sarcoidosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61974404P | 2004-10-18 | 2004-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28946B1 true MA28946B1 (fr) | 2007-10-01 |
Family
ID=36202610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA29848A MA28946B1 (fr) | 2004-10-18 | 2007-04-25 | Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinase |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20080255139A1 (https=) |
| EP (1) | EP1804800B1 (https=) |
| JP (1) | JP2008516898A (https=) |
| KR (1) | KR20070083705A (https=) |
| CN (1) | CN101035535A (https=) |
| AT (1) | ATE492277T1 (https=) |
| AU (1) | AU2005297321A1 (https=) |
| BR (1) | BRPI0517083A (https=) |
| CA (1) | CA2580976A1 (https=) |
| DE (1) | DE602005025514D1 (https=) |
| IL (1) | IL182419A0 (https=) |
| MA (1) | MA28946B1 (https=) |
| MX (1) | MX2007004660A (https=) |
| NO (1) | NO20072501L (https=) |
| NZ (1) | NZ554009A (https=) |
| RU (1) | RU2007118420A (https=) |
| TN (1) | TNSN07141A1 (https=) |
| WO (1) | WO2006042362A1 (https=) |
| ZA (1) | ZA200702316B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009058968A2 (en) * | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
| CN107530430A (zh) * | 2015-01-13 | 2018-01-02 | 国立大学法人京都大学 | 用于预防和/或治疗肌萎缩性侧索硬化症的药剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) * | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| DE60212836T2 (de) * | 2001-05-16 | 2007-01-25 | Gpc Biotech Ag | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten |
| WO2004026930A2 (en) * | 2002-06-26 | 2004-04-01 | The Ohio State University Research Foundation | The method for reducing inflammation using sti-571 or its salt |
-
2005
- 2005-10-17 CN CNA2005800338341A patent/CN101035535A/zh active Pending
- 2005-10-17 JP JP2007535954A patent/JP2008516898A/ja active Pending
- 2005-10-17 CA CA002580976A patent/CA2580976A1/en not_active Abandoned
- 2005-10-17 WO PCT/AU2005/001602 patent/WO2006042362A1/en not_active Ceased
- 2005-10-17 BR BRPI0517083-4A patent/BRPI0517083A/pt not_active IP Right Cessation
- 2005-10-17 US US11/576,967 patent/US20080255139A1/en not_active Abandoned
- 2005-10-17 NZ NZ554009A patent/NZ554009A/en not_active IP Right Cessation
- 2005-10-17 EP EP05793868A patent/EP1804800B1/en not_active Expired - Lifetime
- 2005-10-17 AT AT05793868T patent/ATE492277T1/de not_active IP Right Cessation
- 2005-10-17 AU AU2005297321A patent/AU2005297321A1/en not_active Abandoned
- 2005-10-17 MX MX2007004660A patent/MX2007004660A/es unknown
- 2005-10-17 KR KR1020077008716A patent/KR20070083705A/ko not_active Ceased
- 2005-10-17 DE DE602005025514T patent/DE602005025514D1/de not_active Expired - Lifetime
- 2005-10-17 RU RU2007118420/15A patent/RU2007118420A/ru unknown
-
2007
- 2007-03-20 ZA ZA200702316A patent/ZA200702316B/xx unknown
- 2007-04-10 IL IL182419A patent/IL182419A0/en unknown
- 2007-04-17 TN TNP2007000141A patent/TNSN07141A1/fr unknown
- 2007-04-25 MA MA29848A patent/MA28946B1/fr unknown
- 2007-05-15 NO NO20072501A patent/NO20072501L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005297321A1 (en) | 2006-04-27 |
| DE602005025514D1 (de) | 2011-02-03 |
| NO20072501L (no) | 2007-05-15 |
| KR20070083705A (ko) | 2007-08-24 |
| NZ554009A (en) | 2010-09-30 |
| JP2008516898A (ja) | 2008-05-22 |
| IL182419A0 (en) | 2007-09-20 |
| TNSN07141A1 (en) | 2008-11-21 |
| EP1804800B1 (en) | 2010-12-22 |
| ZA200702316B (en) | 2008-09-25 |
| WO2006042362A1 (en) | 2006-04-27 |
| CA2580976A1 (en) | 2006-04-27 |
| EP1804800A4 (en) | 2008-03-19 |
| BRPI0517083A (pt) | 2008-09-30 |
| ATE492277T1 (de) | 2011-01-15 |
| EP1804800A1 (en) | 2007-07-11 |
| RU2007118420A (ru) | 2008-11-27 |
| CN101035535A (zh) | 2007-09-12 |
| MX2007004660A (es) | 2007-10-17 |
| US20080255139A1 (en) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1332137E (pt) | Tratamento de tumores estromais gastrintestinais | |
| PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| MY159522A (en) | Administration of dipeptidyl peptidase inhibitors | |
| TWI347186B (en) | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| HUE034712T2 (hu) | Amidszármazék és gyógyszer | |
| DK2203444T3 (da) | Faste former af (S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chlor-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoat | |
| NO20075022L (no) | (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav | |
| RU2016149804A (ru) | Производные бензолсульфонамида и их применение в качестве модуляторов орфанного рецептора y, связанного с ретиноевой кислотой | |
| EA201070366A1 (ru) | 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы | |
| NZ590177A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
| MA35636B1 (fr) | Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide | |
| MY146403A (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
| MA28946B1 (fr) | Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinase | |
| NZ593058A (en) | (r)-3-(e)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors | |
| EP2126129A4 (en) | CELL TOD ASSOCIATED PROTEIN KINASE (DAPK1) AND ITS USE IN THE TREATMENT OF CHRONIC LYMPHOCYTE LYMPHIA | |
| IL162983A (en) | Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis | |
| MX2007001990A (es) | Antagonistas del receptor 5-ht7. | |
| HRP20100265T1 (hr) | Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti | |
| JP2008542390A5 (https=) | ||
| NO20056188L (no) | Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes | |
| RU2020127993A (ru) | Терапевтическое средство для лечения гепатоцеллюлярной карциномы | |
| CL2008002461A1 (es) | Compuesto 4-((trans)-2-(4-ciclobutilpiperazina-1-carbonil)ciclopropil)benzamida o un enantiómero, o una sal farmacéuticamente aceptable o una mezcla del mismo | |
| SE0303488D0 (sv) | New use 1X |